(4-Bromo-naphthalen-1-yl)-oxo-acetic acid methyl ester | 848144-22-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (4-Bromo-naphthalen-1-yl)-oxo-acetic acid methyl ester
• 英文别名: methyl 2-(4-bromonaphthalen-1-yl)-2-oxoacetate
• CAS: 848144-22-9
• 化学式: C₁₃H₉BrO₃
• 分子量: 293.117
• InChiKey: NCFROWXAAMKKTE-UHFFFAOYSA-N

物化性质

• 沸点：
  410.6±28.0 °C(Predicted)
• 密度：
  1.532±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-Bromo-naphthalen-1-yl)-oxo-acetic acid methyl ester 、 2-甲基-4-(三丁基锡)吡啶 在 四(三苯基膦)钯 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.17h， 生成 methyl 2-(4-(2-methylpyridin-4-yl)naphthalen-1-yl)-2-oxoacetate
  参考文献：
  名称：

  Optimization of α-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site

  摘要：

  We have optimized a novel series of potent p38 MAP kinase inhibitors based on an alpha-ketoamide scaffold through structure based design that due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME, in vivo PK and efficacy studies show these compounds to have drug-like characteristics and have resulted in the nomination of a development candidate which is currently in phase II clinical trials for the oral treatment of inflammatory conditions. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.102
• 作为产物：
  描述：

  甲基戊酰氯 、 1-溴代萘 在 aluminum (III) chloride 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以37%的产率得到(4-Bromo-naphthalen-1-yl)-oxo-acetic acid methyl ester
  参考文献：
  名称：

  Optimization of α-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site

  摘要：

  We have optimized a novel series of potent p38 MAP kinase inhibitors based on an alpha-ketoamide scaffold through structure based design that due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME, in vivo PK and efficacy studies show these compounds to have drug-like characteristics and have resulted in the nomination of a development candidate which is currently in phase II clinical trials for the oral treatment of inflammatory conditions. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.102

文献信息

• Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
  申请人：MacDonald James E.

  公开号：US20110117055A1

  公开（公告）日：2011-05-19

  Provided herein are hepatitis C virus entry inhibitor oxoacetamide compounds, pharmaceutical compositions thereof, and methods for their use in treatment or prevention of hepatitis C virus infection in a subject in need thereof.

  本文提供了丙型肝炎病毒进入抑制剂羟基乙酰胺化合物，其药物组合物，以及在需要的受试者中用于治疗或预防丙型肝炎病毒感染的方法。
• CYTOKINE INHIBITORS
  申请人：Boman Erik

  公开号：US20100093734A1

  公开（公告）日：2010-04-15

  The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.

  本发明提供了低分子量化合物，可用作细胞因子抑制剂及其组合物。特别是，本发明的化合物可用作抗炎剂。还提供了制备这种药剂的方法，以及其在预防或治疗由细胞因子介导的疾病，如关节炎方面的用途。
• Cytokine inhibitors
  申请人：Boman Erik

  公开号：US20050107399A1

  公开（公告）日：2005-05-19

  The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.

  本发明提供了低分子量化合物，作为细胞因子抑制剂以及其组合物。特别地，本发明的化合物可用作抗炎剂。此外，还提供了制备这些药剂的方法，并将它们用于预防或治疗由细胞因子介导的疾病，例如关节炎。
• Alpha-ketoamides and derivatives thereof
  申请人：Itherx Pharmaceuticals, Inc.

  公开号：US07749999B2

  公开（公告）日：2010-07-06

  The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.

  本发明提供了低分子量化合物，可用作细胞因子抑制剂及其组合物。特别地，本发明的化合物可用作抗炎剂。还提供了制备此类药剂的方法，并用于预防或治疗由细胞因子介导的疾病，如关节炎。
• ALPHA-KETOAMIDES AND DERIVATIVES THEREOF
  申请人：Boman Erik

  公开号：US20100273797A1

  公开（公告）日：2010-10-28

  The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions medicated by cytokines such as arthritis.

  本发明提供了低分子量化合物，可用作细胞因子抑制剂及其组合物。特别地，本发明的化合物可用作抗炎剂。还提供了制备这些药剂的方法，并将其用于预防或治疗由细胞因子介导的疾病，例如关节炎。